Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Chemical modification of siRNAs for in vivo use.

Behlke MA.

Oligonucleotides. 2008 Dec;18(4):305-19. doi: 10.1089/oli.2008.0164. Review.

PMID:
19025401
2.

Chemical modifications on siRNAs avoid Toll-like-receptor-mediated activation of the hepatic immune system in vivo and in vitro.

Broering R, Real CI, John MJ, Jahn-Hofmann K, Ickenstein LM, Kleinehr K, Paul A, Gibbert K, Dittmer U, Gerken G, Schlaak JF.

Int Immunol. 2014 Jan;26(1):35-46. doi: 10.1093/intimm/dxt040. Epub 2013 Sep 24.

PMID:
24065781
3.

Engineering small interfering RNAs by strategic chemical modification.

Bramsen JB, Kjems J.

Methods Mol Biol. 2013;942:87-109. doi: 10.1007/978-1-62703-119-6_5.

PMID:
23027047
4.

Therapeutic targeting in the silent era: advances in non-viral siRNA delivery.

Guo J, Fisher KA, Darcy R, Cryan JF, O'Driscoll C.

Mol Biosyst. 2010 Jul;6(7):1143-61. doi: 10.1039/c001050m. Epub 2010 Apr 29. Review.

PMID:
20431817
5.

Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology.

Gomes-da-Silva LC, Simões S, Moreira JN.

Cell Mol Life Sci. 2014 Apr;71(8):1417-38. doi: 10.1007/s00018-013-1502-2. Epub 2013 Nov 13. Review.

PMID:
24221135
6.

Recent progress in chemically modified siRNAs.

Gaglione M, Messere A.

Mini Rev Med Chem. 2010 Jun;10(7):578-95. Review.

PMID:
20500149
7.
8.

Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo.

Laursen MB, Pakula MM, Gao S, Fluiter K, Mook OR, Baas F, Langklaer N, Wengel SL, Wengel J, Kjems J, Bramsen JB.

Mol Biosyst. 2010 May;6(5):862-70. doi: 10.1039/b918869j. Epub 2010 Feb 9.

PMID:
20567772
9.

Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs.

Ge Q, Dallas A, Ilves H, Shorenstein J, Behlke MA, Johnston BH.

RNA. 2010 Jan;16(1):118-30. doi: 10.1261/rna.1901810. Epub 2009 Nov 30.

10.

Therapeutic siRNA: principles, challenges, and strategies.

Gavrilov K, Saltzman WM.

Yale J Biol Med. 2012 Jun;85(2):187-200. Epub 2012 Jun 25. Review.

11.

Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing.

Bartlett DW, Davis ME.

Biotechnol Bioeng. 2007 Jul 1;97(4):909-21.

PMID:
17154307
12.

Improved serum stability and biophysical properties of siRNAs following chemical modifications.

Cho IS, Kim J, Lim DH, Ahn HC, Kim H, Lee KB, Lee YS.

Biotechnol Lett. 2008 Nov;30(11):1901-8. doi: 10.1007/s10529-008-9776-4. Epub 2008 Jun 25.

PMID:
18575806
13.

Exploring chemical modifications for siRNA therapeutics: a structural and functional outlook.

Shukla S, Sumaria CS, Pradeepkumar PI.

ChemMedChem. 2010 Mar 1;5(3):328-49. doi: 10.1002/cmdc.200900444. Review.

PMID:
20043313
14.

RNA interference in vivo: toward synthetic small inhibitory RNA-based therapeutics.

de Fougerolles A, Manoharan M, Meyers R, Vornlocher HP.

Methods Enzymol. 2005;392:278-96.

PMID:
15644187
15.

A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity.

Bramsen JB, Laursen MB, Nielsen AF, Hansen TB, Bus C, Langkjaer N, Babu BR, Højland T, Abramov M, Van Aerschot A, Odadzic D, Smicius R, Haas J, Andree C, Barman J, Wenska M, Srivastava P, Zhou C, Honcharenko D, Hess S, Müller E, Bobkov GV, Mikhailov SN, Fava E, Meyer TF, Chattopadhyaya J, Zerial M, Engels JW, Herdewijn P, Wengel J, Kjems J.

Nucleic Acids Res. 2009 May;37(9):2867-81. doi: 10.1093/nar/gkp106. Epub 2009 Mar 12.

16.

RNA major groove modifications improve siRNA stability and biological activity.

Terrazas M, Kool ET.

Nucleic Acids Res. 2009 Feb;37(2):346-53. doi: 10.1093/nar/gkn958. Epub 2008 Nov 28.

17.

Chemical modification of siRNA.

Chernolovskaya EL, Zenkova MA.

Curr Opin Mol Ther. 2010 Apr;12(2):158-67. Review.

PMID:
20373259
18.

siRNA function in RNAi: a chemical modification analysis.

Chiu YL, Rana TM.

RNA. 2003 Sep;9(9):1034-48.

19.

Chemical modification of siRNAs to improve serum stability without loss of efficacy.

Choung S, Kim YJ, Kim S, Park HO, Choi YC.

Biochem Biophys Res Commun. 2006 Apr 14;342(3):919-27.

PMID:
16598842
20.

Synthesis and properties of modified siRNA having amide-linked oligoribonucleosides at their 3' overhang regions.

Iwase R, Miyao H, Toyama T, Nishimori K.

Nucleic Acids Symp Ser (Oxf). 2006;(50):175-6.

PMID:
17150874

Supplemental Content

Support Center